Skip to main content

Table 1 Clinical characteristics of patients with HFpEF and non-HF patients in HCM

From: Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy

Parameters

All (n=1178)

HFpEF# (n=513)

Non-HF# (n=665)

P value*

Age at evaluation (years)

49±14

50±14

48±14

0.146

Female

415 (35.2)

229 (44.6)

186 (28.0)

< 0.001

MWT (mm)

23 (20–26)

24 (21–28)

22 (19–25)

< 0.001

LVEF (%)

68±8

69±7

68±6

0.027

LVedd (mm)

44±6

43±6

44±5

< 0.001

Unexplained syncope

149 (12.6)

75 (14.6)

74 (11.1)

0.070

Atrial fibrillation

230 (19.5)

140 (27.3)

90 (13.5)

< 0.001

Maximal LVOT gradient

44 (10–80)

64 (29–94)

25 (8–67)

< 0.001

NT-proBNP

988.0 (494.1–1934.4)

1807.0 (1225.0–2892.6)

536.8 (304.6–796.8)

< 0.001

NYHA class

    

 I

385 (32.7)

0 (0.0)

385 (57.9)

< 0.001

 II

514 (43.6)

313 (61.0)

201 (30.2)

< 0.001

 III/IV

279 (23.7)

200 (39.0)

79 (11.9)

< 0.001

Medicine treatment

    

 Beta-blockers

861 (73.1)

387 (75.4)

474 (71.3)

0.110

 ACEI/ARBs

232 (19.7)

70 (13.6)

162 (24.4)

< 0.001

 Calcium-channel blocker

230 (19.5)

87 (17.0)

143 (21.5)

0.051

 Diuretic

269 (22.8)

160 (31.2)

109 (16.4)

< 0.001

  1. In our cohort, the data on the maximal LVOT gradient were not available in 15 (1.3%) patients and the missing values were imputed using the median.
  2. Values are presented as the mean±SD, median (interquartile range) or n (%)
  3. AHA American Heart Association, LVedd left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, LVOT left ventricular outflow tract, MWT maximal wall thickness, NT-proBNP N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association
  4. #Heart failure phenotypes were identified using AHA criteria
  5. *Comparison between patients with HFpEF and non-HF patients
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us